发明名称 |
COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER |
摘要 |
The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof. |
申请公布号 |
US2015132253(A1) |
申请公布日期 |
2015.05.14 |
申请号 |
US201314401899 |
申请日期 |
2013.05.21 |
申请人 |
GANYMED PHARMACEUTICALS AG ;TRON - Translationale Onkologie an der Johannes Gutenberg-Universität Mainz germeinnützige GmbH |
发明人 |
Sahin Ugur;Türeci Özlem;Mitnacht-Kraus Rita;Jacobs Stefan Denis;Utsch Magdalena Jadwiga;Heinz Cornelia Adriana Maria;Stadler Christiane Regina |
分类号 |
C07K16/30;A61K31/704;A61K31/513;A61K31/555;A61K38/20;A61K31/337;A61K33/24;A61K31/519;A61K31/675;A61K31/663;A61K39/395;A61K31/4745 |
主分类号 |
C07K16/30 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treating or preventing a cancer disease comprising administering to a patient an antibody having the ability of binding to CLDN18.2 in combination with an agent stabilizing or increasing expression of CLDN18.2. |
地址 |
Mainz DE |